# US 2023/0069076 A1 · Compositions for the treatment of glaucoma and ocular hypertension

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0069076 A1
- Document ID: US20230069076A1
- Status: Published application
- Kind: A1
- Application number: 17/760,012
- Filed: 2021-02-03
- Published: 2023-03-02
- Earliest claimed: 2020-02-05
- Assignees: Nicox S.A.
- Applicants: Nicox S.A.
- Inventors: Nicoletta ALMIRANTE; Stefania BRAMBILLA; Francesco IMPAGNATIELLO; Elena BASTIA; Corinna GALLI
- Web page: https://patentgrep.com/patent/US20230069076A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A61K 31/5578: having a pentalene ring system, e.g. carbacyclin, iloprost
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to ophthalmic compositions comprising a nitric oxide releasing phosphodiesterase type 5 inhibitor (NO-PDE5 inhibitor) and a prostaglandin analog, and to the use of these ophthalmic compositions for the treatment of all forms of glaucoma or ocular hypertension as well as eyes diseases or conditions associated with elevated intraocular pressure. The NO-PDE5 inhibitor is selected from the following compounds: [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy) hexanoate (Compound (1)), [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 3-[(2S)-2,3-bis(nitrooxy)propoxy]propanoate (Compound (1A)) or 2-{4-[3-(5-Ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxybenzene-1-sulfonyl]piperazin-1-yl}ethyl 3-[(2S)-2,3-bis(nitrooxy) propoxy]propanoate (Compound (2)). The prostaglandin analog is selected from latanoprost, bimatoprost, travoprost or tafluprost.

## Claims

### Claim 1

An ophthalmic composition comprising:
i) a nitric oxide releasing phosphodiesterase type 5 inhibitor selected from:
[(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl] carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate or a pharmaceutically acceptable salt thereof,
ii) a prostaglandin analog selected from: latanoprost, bimatoprost, travoprost or tafluprost.

### Claim 2 (depends on 1)

The composition according to claim 1 wherein the nitric oxide releasing phosphodiesterase type 5 inhibitor is a pharmaceutically acceptable salt selected from:
2-hydroxypropane-1,2,3-tricarboxylic acid [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl) pyrrolidin-2-yl] methyl 6-(nitrooxy)hexanoate (1/1), or
(2E)-but-2-enedioic acid [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl} pyrimidin-2-yl)pyrrolidin-2-yl] methyl 6-(nitrooxy)hexanoate (1/1), or
(2Z)-but-2-enedioic acid [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl) methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy) hexanoate (1/1).

### Claim 3 (depends on 1)

The composition according to claim 1, wherein the prostaglandin analog is latanoprost.

### Claim 4 (depends on 1)

The composition according to claim 1, wherein the prostaglandin analog is bimatoprost.

### Claim 5 (depends on 1)

The composition according to claim 1, wherein the prostaglandin analog is travoprost.

### Claim 6 (depends on 1)

The composition according to claim 1, wherein the prostaglandin analog is tafluprost.

### Claim 7 (depends on 1)

An ophthalmic composition according to claim 1, for use as medicament.

### Claim 8 (depends on 1)

An ophthalmic composition according to claim 1, for use in a method of treating glaucoma, ocular hypertension or a disease or a condition associated with elevated intraocular pressure.

### Claim 9 (depends on 8)

The ophthalmic composition for use according to claim 8 wherein the condition associated with elevated intraocular pressure is drug-induced elevated intraocular pressure that occurs during the treatment of retinopathies including retinopathy of prematurity, retinal vein occlusion or diabetic macular edema or age-related macular degeneration.

### Claim 10 (depends on 1)

The ophthalmic composition according to claim 1, for use in the treatment of normal tension glaucoma.

### Claim 11 (depends on 8)

The ophthalmic composition for use according to claim 8, wherein the nitric oxide releasing phosphodiesterase type 5 inhibitor or a pharmaceutically acceptable salt thereof is applied to eye(s), simultaneously, separately or sequentially to the application of the prostaglandin analog to the eye(s).

### Claim 12 (depends on 1)

An ophthalmic pharmaceutical formulation comprising a composition according to claim 1, and at least a pharmaceutically acceptable excipient and/or vehicle.

### Claim 13

A kit comprising:
i) a nitric oxide releasing phosphodiesterase type 5 inhibitor selected from:
[(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl] carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate or a pharmaceutically acceptable salt thereof,
ii) a prostaglandin analog selected from: latanoprost, bimatoprost, travoprost or tafluprost, for simultaneous or separate administration of the nitric oxide releasing phosphodiesterase type 5 inhibitor and of the prostaglandin analog.
